2 recruiting, 1 completed, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow HitGen Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma HG146 - Adenoid Cystic Carcinoma, Head and Neck Cancer | Phase 2 | Recruiting | HitGen Inc. | 140 | 2024-12-13 | 2026-09-21 |
| A Study of HG381 Administered to Patients With Advanced Solid Tumors HG381 - Advanced Solid Tumor | Phase 1 | Recruiting | HitGen Inc. | 57 | 2021-10-18 | 2026-09-17 |
| Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma HG146, PD-(L)1 antibody - Solid Tumor, Lymphoma | Phase 1 | Completed | HitGen Inc. | 24 | 2021-09-23 | 2026-09-21 |
| A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma HG146 - Multiple Myeloma, Relapsed and Refractory Multiple Myeloma | Phase 1 | Terminated | HitGen Inc. | 3 | 2019-01-12 | 2024-10-10 |
Carcinoma, Adenoid Cystic (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Multiple Myeloma (1) · Recurrence (1)
Injections (1) · spartalizumab (1)
China (4)
Jianming Xu, M.D (1) · Ting Liu, M.D. (1) · Ye Guo (1) · Yuankai Shi (1)